Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.
Read Full NewsNew York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.
The drug was previously approved for stage 2 T1D.
Findings suggest young females should be assessed and, if at risk, monitored.
Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.
Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.
The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.
Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.
1.
Best foot forward—chemo care should include podiatry, say researchers
2.
Prior authorizations draining time, energy from many cancer patients
3.
Implant-based reconstruction linked to increased risk of breast lymphomas
4.
Similar survival seen with simple versus radical hysterectomy for cervical cancer
5.
New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada
1.
Liquid Biopsy in Hematologic Malignancies: Current Evidence and Clinical Applications
2.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
3.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
4.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
5.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
2.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
Thromboprophylaxis In Medical Settings
5.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge